Skip to main navigation
  • Skip to main content
  • Skip to primary sidebar
Imara

Top Navigation

  • Careers
  • Contact Us

Investor Relations

  • Who We Are
    • Management
    • Board of Directors
  • Our Programs
    • IMR-687 & PDE9
    • Posters & Publications
    • Clinical Trials
  • Patients & Families
    • Resources
    • Advocacy Groups
    • Imara Expanded Access Policy
  • Investors
    • Press Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Careers
  • Contact Us

Investors

Breadcrumb

Investors » Investor Relations

Investor Relations

Corporate Profile

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our lead product candidate, IMR-687, an oral, once-daily, potentially disease-modifying treatment in clinical development for sickle cell disease (SCD) and β-thalassemia. IMR-687 is uniquely designed as a highly selective, potent small molecule inhibitor of PDE9 with a multimodal mechanism that acts on red blood cells, white blood cells, adhesion mediators and other cell types. Our goal is to leverage the differentiated mechanism of action, ease of administration and stable drug properties of IMR-687 to potentially serve a broad range of patients suffering from hemoglobinopathies around the world, including those in underserved regions.
Change
Volume
52 Week High
52 Week Low
Jan 28, 2021 3:14 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Jan 20, 2021
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
Jan 06, 2021
Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease
Dec 07, 2020
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
Events
Nov 5, 2020 at 8:30 AM EST
Imara Inc Q3 Earnings Conference Call & Webcast
Sep 17, 2020 at 10:15 AM EDT
Morgan Stanley 18th Annual Global Healthcare Conference
Sep 10, 2020 at 4:15 PM EDT
Citi’s 15th Annual Biopharma Virtual Conference

Footer Social Link

Imara, Inc.
116 Huntington Ave.
6th Floor
Boston, MA 02116
T: 617-206-2020
E: info@imaratx.com

Sign Up for Email Updates
Privacy Policy
Terms of Use
© 2021 Imara, Inc.